Metastatic bone cancer occurs when cancer cells spread from primary tumors, such as those in the breast, prostate, or lung, to the bones. According to a 2024 study by Jianqiang Lai et al., the incidence of bone metastasis in solid tumors is 6.9% at 5 years and 8.4% at 10 years post-diagnosis. Therapeutic approaches include bisphosphonates, denosumab, radiopharmaceuticals, and emerging immunotherapies. The growing focus on bone-targeted treatments is driven by the need to reduce skeletal-related events and improve patient quality of life. According to the metastatic bone cancer pipeline analysis by Expert Market Research, research and development in this area are expanding steadily, with new therapies showing potential to transform clinical management and outcomes in the coming years.
Major companies involved in the metastatic bone cancer pipeline analysis include JMT-Bio Inc., Suzhou Suncadia Biopharmaceuticals Co., Ltd., and others.
Leading drugs currently in the pipeline include JMT103, ALMB-0168, and others.
The drug pipeline for metastatic bone cancer is expected to expand due to increasing focus on targeted therapies, novel immuno-oncology agents, and combination treatments, driving accelerated clinical development and market diversification.
The Metastatic Bone Cancer Pipeline Analysis Report by Expert Market Research gives comprehensive insights into metastatic bone cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for metastatic bone cancer. The metastatic bone cancer report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The metastatic bone cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with metastatic bone cancer treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to metastatic bone cancer.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Metastatic bone cancer occurs when cancer cells spread from a primary site, such as the breast, prostate, or lung, to the bones. This process usually happens through the bloodstream or lymphatic system, causing bone pain, fractures, and reduced mobility.
Metastatic bone cancer treatment includes chemotherapy, radiation therapy, targeted therapy, surgery, bisphosphonates, and denosumab. These approaches focus on reducing pain, preventing fractures, slowing disease progression, and improving patients’ quality of life. Researchers reported progress with CADD522, a novel drug in the metastatic bone cancer market pipeline. The therapy showed promising preclinical results by targeting a cancer-driving gene, significantly improving survival outcomes without conventional chemotherapy.
According to Jianqiang Lai et al. (2024), the incidence of bone metastasis in solid tumors is 6.9% at five years and 8.4% at ten years post-diagnosis. As per Peiran Liu et al. (2025), malignant bone tumors account for about 6% of childhood cancers, with an annual incidence of 8.7 per million children under 20 years in the United States, translating to 650-700 new cases annually. This includes approximately 400 osteosarcoma and 200 Ewing’s sarcoma cases. These figures highlight the growing need for advanced therapeutic options in metastatic bone cancer.
This section of the report covers the analysis of metastatic bone cancer drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The metastatic bone cancer pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total metastatic bone cancer clinical trials, with 54%. It is followed by phase I at 32%, and phase III at 10%. The strong presence across all phases highlights a healthy and advancing pipeline, supporting innovation and promising future growth in the metastatic bone cancer treatment.
The drug molecule categories covered under the metastatic bone cancer pipeline analysis include small molecules, monoclonal antibodies, antibody-drug conjugates (ADCs), peptides, and proteins. The metastatic bone cancer report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for metastatic bone cancer. Bone-targeted drug therapies are gaining traction in the metastatic bone cancer pipeline to improve patient outcomes. For instance, ZetaMet™ (Zeta-BC-003) from Zetagen Therapeutics is under clinical evaluation for metastatic breast cancer to bone. The therapy aims to suspend tumor progression, inhibit pain, and regenerate bone tissue, with the potential to enhance survival rates and overall quality of life.
The EMR report for the metastatic bone cancer pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed metastatic bone cancer therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in metastatic bone cancer clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for metastatic bone cancer. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of metastatic bone cancer drug candidates.
JMT103, sponsored by Shanghai JMT-Bio Inc., is a fully humanized monoclonal antibody designed to inhibit RANK-RANKL signaling, aiming to prevent bone-related events in patients with bone metastases from malignant solid tumors. It is in a Phase III, multicenter, randomized, double-blind study that is evaluating the efficacy and safety of JMT103 compared to zoledronic acid. The study is also examining whether JMT103 can provide rapid, significant, and sustained suppression of bone resorption while offering an improved safety profile.
ALMB-0168, developed by AlaMab Therapeutics (Shanghai) Inc., is entering Phase IIa trials to evaluate its efficacy in patients with solid tumors and bone metastasis whose prior treatments have failed. This humanized monoclonal antibody is binding to the extracellular domain of Cx43 and is activating hemichannels in osteocytes, thereby releasing ATP and promoting anti-cancer immune responses. The study is examining its ability to reduce tumor growth, improve survival, and address skeletal-related events.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Metastatic Bone Cancer Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for metastatic bone cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into metastatic bone cancer collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share